Lutetium Vipivotide Tetraxetan
A brief description of the project mission
Some fancy text
Some fancy text
Some fancy text
Available as an intravenous solution at the strength of 27 mCi/1mL.
Needs to be stored according to radio-pharmaceutical storage guidelines.
May cause adverse effects where dose modification is required.
Mechanism of Action:
Absorption:
Maximum blood concentration = 6.58 ng/mL
Distribution:
Volume of distribution = 123 L
60% to 70% bound to human plasma proteins
Elimination:
Elimination half-life = 41.6 hours (68.8%)
Clearance (CL) = 2.04 L/h (31.5%)
Primarily eliminated renally
Pluvicto™ (Lutetium-177 Vipivotide Tetraxetan) FDA approved in the VISION Phase III randomized, multicenter, open-labeled clinical trial of 831 patients with progressive PSMA-positive mCPRC.
Some fancy text
Some fancy text